Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE 2: IcoSema versus semaglutide in adults with type 2 diabetes inadequately controlled on a GLP-1 receptor agonist
2020-005308-21Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of icosema and semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Oct 2021; status: completed.
02
Drugs
icosemasemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-005308-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005308-21.